2025³âµµ ¼îÆ®ÄÚ½º
Monday, 10 November, 2025
SC1: Best Practices and Advanced Applications for Label-Free Interaction Analysis in Therapeutic Antibody Discovery
Yasmina Abdiche, PhD, Senior Vice President, Exploratory Research, OmniAb Inc.
SC2: Best Practices for Targeting GCPRs, Ion Channels, and Transporters with Monoclonal Antibodies
Ross Chambers, PhD, Vice President, Antibody Discovery, Integral Molecular, Inc.
SC3: Developability of Bispecific Antibodies
Nimish Gera, PhD, Vice President, Biologics, Mythic Therapeutics
SC4: In silico and Machine Learning Tools for Antibody Design and Developability Predictions
Rahmad Akbar, PhD, Senior Data Scientist, Antibody Design, Novo Nordisk
Vinodh B. Kurella, PhD, Biotherapeutic Computational Modeler, Takeda Pharmaceuticals, Inc.
Odysseas Vavourakis, Generative Antibody Design, University of Oxford
* ÁÖÃÖÃø »çÁ¤¿¡ µû¶ó »çÀü ¿¹°í¾øÀÌ ÇÁ·Î±×·¥ÀÌ º¯°æµÉ ¼ö ÀÖ½À´Ï´Ù.
ÄÁÆÛ·±½º ÇÁ·Î±×·¥

°øÇÐ ½ºÆ®¸²
- Display of Biologics
¹ÙÀÌ¿À·ÎÁ÷½ºÀÇ µð½ºÇ÷¹ÀÌ - Engineering Antibodies
Ç×ü °øÇÐ - Machine Learning Part 2
±â°èÇнÀ ÆÄÆ® 2

Ÿ°Ù ½ºÆ®¸²
- Antibody-Based Therapies
Ç×ü ±â¹Ý ÀǾà - Emerging Targets
½Å±Ô Ÿ°Ù - Membrane Protein Targets
¸·´Ü¹éÁú Ÿ°Ù

ÀÌÁ߯¯À̼º ½ºÆ®¸²
- Safety & Efficacy
¾ÈÀü¼º¡¤À¯È¿¼º - Advancing Multispecifics
´ÙÁß Æ¯À̼º Ç×üÀÇ Áøº¸ - Engineering Bispecifics
ÀÌÁ߯¯À̼ºÇ×ü °øÇÐ

¸é¿ªÄ¡·á ½ºÆ®¸²
- Immunoengineering
¸é¿ª °øÇÐ - Innovative CAR Therapy
Çõ½ÅÀûÀÎ CAR ¿ä¹ý - Next-Gen Immunotherapies
Â÷¼¼´ë ¸é¿ªÄ¡·á

ºÐ¼®¹ý ½ºÆ®¸²
- Optimisation & Developability
ÃÖÀûÈ¡¤°³¹ß °¡´É¼º - Analytical Characterisation
ºÐ¼®¹ý Ư¼º Æò°¡ - Protein Stability & Formulation
´Ü¹éÁú ¾ÈÁ¤¼º¡¤Á¦Çü

¹ßÇö ½ºÆ®¸²
- Leveraging Data Science
µ¥ÀÌÅÍ »çÀ̾𽺠Ȱ¿ë - Optimising Expression
¹ßÇö ÃÖÀûÈ - Developing Workflows
¿öÅ©ÇÃ·Î¿ì °³¹ß

±â°èÇнÀ ½ºÆ®¸²
- Intro to Machine Learning
±â°èÇнÀ ÀÔ¹® - Machine Learning Part 1
±â°èÇнÀ ÆÄÆ® 1 - Machine Learning Part 2
±â°èÇнÀ ÆÄÆ® 2

Á¾¾ç ½ºÆ®¸²
- Antibody-Based Therapies
Ç×ü ±â¹Ý ÀǾà - Engineering ADCs
ADC °øÇÐ - Next-Gen Immunotherapies
Â÷¼¼´ë ¸é¿ªÄ¡·á